SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-22-005819
Filing Date
2022-03-02
Accepted
2022-03-02 16:26:22
Documents
13
Period of Report
2022-02-28
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 47849
2 ex10-1.htm EX-10.1 25688
  Complete submission text file 0001493152-22-005819.txt   250913

Data Files

Seq Description Document Type Size
3 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT prph-20220228.xsd EX-101.SCH 3045
4 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT prph-20220228_lab.xml EX-101.LAB 34476
5 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT prph-20220228_pre.xml EX-101.PRE 22603
7 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3490
Mailing Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530
Business Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530 (215) 345-0919
ProPhase Labs, Inc. (Filer) CIK: 0000868278 (see all company filings)

IRS No.: 232577138 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-21617 | Film No.: 22703885
SIC: 2834 Pharmaceutical Preparations